{
    "nctId": "NCT00516724",
    "briefTitle": "Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel",
    "officialTitle": "A Phase I, Open-Label Study to Assess the Safety and Tolerability of KU-0059436 in Combination With Carboplatin, KU-0059436 in Combination With a Paclitaxel/Carboplatin T/C Doublet and KU-0059436 in Combination With Paclitaxel in the Treatment of Patients With Advanced Solid Tumours",
    "overallStatus": "COMPLETED",
    "conditions": "Triple Negative Metastatic Breast Cancer, Advanced Ovarian Cancer, Carboplatin, Paclitaxel",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 189,
    "primaryOutcomeMeasure": "To establish the maximum tolerated dose (MTD) of KU 0059436 in combination with Paclitaxel/Carboplatin",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female patients with a histologically or cytologically diagnosed malignant solid tumour\n* Adequate bone marrow, hepatic and renal function\n* Performance status of no more than 2 ( ECOG scale).\n\nExclusion Criteria:\n\n* Any chemotherapy, radiotherapy ( except palliative), endocrine or immunotherapy within 4 weeks prior to entry\n* Major surgery with 4 weeks of entering the study and must have recovered from effects of the major surgery\n* More than two previous courses of platinum-containing chemotherapy\n* Heavily pre-treated patients(\\> 2 courses of previous chemotherapy and/or extensive irradiation leading to bone marrow deficiency) will be excluded from the study",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}